Insights from genome-wide association studies of drug response

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 299-310

  Zhou, Kaixin ^a   Pearson, Ewan R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

drug response; genetics; GWAS; pharmacogenomics

Indexed keywords

ADVERSE DRUG REACTION; DRUG EFFICACY; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; MENDELIAN DISEASE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

DRUG TOXICITY; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS;

EID: 84872247183     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011112-140237     Document Type: Review

References (69)

1. Daly AK. 2010. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11:241-46
2. Roden DM, Wilke RA, Kroemer HK, Stein CM. 2011. Pharmacogenomics: the genetics of variable drug responses. Circulation 123:1661-70
3. Goldstein DB, Tate SK, Sisodiya SM. 2003. Pharmacogenetics goes genomic. Nat. Rev. Genet. 4:937-47
4. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, et al. 2008. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9:356-69
5. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. 2009. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA 106:9362-67
6. McCarthy MI, Zeggini E. 2007. Genome-wide association scans for type 2 diabetes: new insights into biology and therapy. Trends Pharmacol. Sci. 28:598-601
7. Perry JR, FraylingTM. 2008. New gene variants alter type 2 diabetes risk predominantly through reduced beta-cell function. Curr. Opin. Clin. Nutr. Metab. Care 11:371-77
8. Altman RB, Kroemer HK, McCarty CA, Ratain MJ, Roden D. 2011. Pharmacogenomics:Will the promise be fulfilled? Nat. Rev. Genet. 12:69-73
9. Guttmacher AE, McGuire AL, Ponder B, Stefansson K. 2010. Personalized genomic information: preparing for the future of genetic medicine. Nat. Rev. Genet. 11:161-65
10. Roden DM, Tyndale RF. 2011. Pharmacogenomics at the tipping point: challenges and opportunities. Clin. Pharmacol. Ther. 89:323-27
11. Rogowski WH, Grosse SD, Khoury MJ. 2009. Challenges of translating genetic tests into clinical and public health practice. Nat. Rev. Genet. 10:489-95
12. WangL, McLeodHL, WeinshilboumRM.2011. Genomics and drug response. N. Engl. J.Med. 364:1144-53
13. Daly AK. 2012. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52:21-35
14. International HapMap Consortium. 2005. A haplotype map of the human genome. Nature 437:1299-320
15. Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, et al. 2010. Integrating common and rare genetic variation in diverse human populations. Nature 467:52-58
16. Barrett JC, Cardon LR. 2006. Evaluating coverage of genome-wide association studies. Nat. Genet. 38:659-62
17. Visscher PM, Brown MA, McCarthy MI, Yang J. 2012. Five years of GWAS discovery. Am. J. Hum. Genet. 90:7-24
18. Singleton AB, Hardy J, Traynor BJ, Houlden H. 2010. Towards a complete resolution of the genetic architecture of disease. Trends Genet. 26:438-42
19. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, et al. 2010. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467:832-38
20. Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, et al. 2010. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42:570-75
21. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, et al. 2010. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42:565-69
22. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. 2009. Finding the missing heritability of complex diseases. Nature 461:747-53
23. Hirschhorn JN. 2009. Genomewide association studies-illuminating biologic pathways. N. Engl. J.Med. 360:1699-701
24. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. 2010. Rare variants create synthetic genome-wide associations. PLoS Biol. 8:e1000294
25. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. 2010. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 42:579-89
26. Bonnefond A, Clement N, Fawcett K, Yengo L, Vaillant E, et al. 2012. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat. Genet. 44:297-301
27. Danoy P, Pryce K, Hadler J, Bradbury LA, Farrar C, et al. 2010. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet. 6:e1001195
28. Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, et al. 2010. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat. Genet. 42:123-27
29. Song IH, Poddubnyy D. 2011. New treatment targets in ankylosing spondylitis and other spondyloarthritides. Curr. Opin. Rheumatol. 23:346-51
30. Crowley JJ, Sullivan PF, McLeodHL. 2009. Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 10:161-63
31. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, et al. 2009. HLA-B-5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41:816-19
32. Link E, Parish S, Armitage J, Bowman L, Heath S, et al. 2008. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359:789-99
33. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, et al. 2011. HLA-A?3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364:1134-43
34. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, et al. 2010. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42:711-14
35. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, et al. 2011. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12:745-55
36. di Iulio J, Rotger M. 2011. Pharmacogenomics:What is next? Front. Pharmacol. 2:86
37. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. 2005. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther. 78:540-50
38. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, et al. 2005. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5:262-70
39. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, et al. 2008.Agenome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-27
40. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, et al. 2009. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5:e1000433
41. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401
42. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-αand ribavirin therapy. Nat. Genet. 41:1100-4
43. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. 2009. Genome-wide association of IL28B with response to pegylated interferon- αand ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-9
44. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801
45. Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, et al. 2007. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 56:2178-82
46. Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, et al. 2011. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365:1173-83
47. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, et al. 2011. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43:117-20
48. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Investig. 108:1167-74
49. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, et al. 2010. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Investig. 120:2355-69
50. Kohane IS. 2011. Using electronic health records to drive discovery in disease genomics. Nat. Rev. Genet. 12:417-28
51. Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, et al. 2011. The emerging role of electronicmedical records in pharmacogenomics. Clin. Pharmacol. Ther. 89:379-86
52. Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, et al. 2008. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84:362-69
53. McCarty CA, Chapman-Stone D, Derfus T, Giampietro PF, Fost N. 2008. Community consultation and communication for a population-based DNA biobank: the Marshfield clinic personalized medicine research project. Am. J. Med. Genet. A 146A:3026-33
54. Ritchie MD, Denny JC, Crawford DC, Ramirez AH, Weiner JB, et al. 2010. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am. J. Hum. Genet. 86:560-72
55. Kurreeman F, Liao K, Chibnik L, Hickey B, Stahl E, et al. 2011. Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. Am. J. Hum. Genet. 88:57-69
56. Kullo IJ, Ding K, Jouni H, Smith CY, Chute CG. 2010. A genome-wide association study of red blood cell traits using the electronic medical record. PLoS One 5:e13011
57. Delaney JT, Ramirez AH, Bowton E, Pulley JM, Basford MA, et al. 2012. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin. Pharmacol. Ther. 91:257-63
58. Purcell S, Cherny SS, Sham PC. 2003. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19:149-50
59. Guey LT, Kravic J, Melander O, Burtt NP, Laramie JM, et al. 2011. Power in the phenotypic extremes: a simulation study of power in discovery and replication of rare variants. Genet. Epidemiol. 35:236-46
60. Wang K, Li M, Hakonarson H. 2010. Analysing biological pathways in genome-wide association studies. Nat. Rev. Genet. 11:843-54
61. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, et al. 2007. Population genomics of human gene expression. Nat. Genet. 39:1217-24
62. Schadt EE, Molony C, Chudin E, Hao K, Yang X, et al. 2008. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6:e107
63. Goring HH, Curran JE, Johnson MP, Dyer TD, Charlesworth J, et al. 2007. Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nat. Genet. 39:1208-16
64. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, et al. 2009. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 325:1246-50
65. Small KS, Hedman AK, Grundberg E, Nica AC, Thorleifsson G, et al. 2011. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat. Genet. 43:561-64
66. Kasarskis A, Yang X, Schadt E. 2011. Integrative genomics strategies to elucidate the complexity of drug response. Pharmacogenomics 12:1695-715
67. So HC, Li M, Sham PC. 2011. Uncovering the total heritability explained by all true susceptibility variants in a genome-wide association study. Genet. Epidemiol. 35:447-56
68. Yang J, Manolio TA, Pasquale LR, Boerwinkle E, Caporaso N, et al. 2011. Genome partitioning of genetic variation for complex traits using common SNPs. Nat. Genet. 43:519-25
69. Yang J, Lee SH, Goddard ME, Visscher PM. 2011. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88:76-82